Study S000669

A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07523633
Acronym: HASHTAG
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 100
Start: 2026-04-30
Primary completion: 2028-04-30
Lead sponsor: Anders Fink-Jensen, MD, DMSci
Conditions: Cannabis Use Disorder; Cannabis Use Disorders; Cannabis Abuse; Cannabis Dependence; Cannabis Addiction
Interventions: DRUG:semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1327-8749; REGISTRY:2025-524163-21; NIH:2025

Registered primary outcomes

Cannabis consumption [From baseline to week 20.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.